Baxter International Inc (BAX) Stake Raised by LS Investment Advisors LLC
LS Investment Advisors LLC increased its stake in Baxter International Inc (NYSE:BAX) by 75.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,375 shares of the medical instruments supplier’s stock after buying an additional 13,897 shares during the quarter. LS Investment Advisors LLC’s holdings in Baxter International were worth $2,093,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BAX. Sterling Capital Management LLC acquired a new stake in shares of Baxter International in the 2nd quarter valued at approximately $278,000. Gofen & Glossberg LLC IL lifted its holdings in Baxter International by 1.3% during the 2nd quarter. Gofen & Glossberg LLC IL now owns 15,354 shares of the medical instruments supplier’s stock valued at $930,000 after purchasing an additional 203 shares during the last quarter. Archford Capital Strategies LLC lifted its holdings in Baxter International by 932.7% during the 2nd quarter. Archford Capital Strategies LLC now owns 13,787 shares of the medical instruments supplier’s stock valued at $1,466,000 after purchasing an additional 12,452 shares during the last quarter. Toronto Dominion Bank lifted its holdings in Baxter International by 20.0% during the 2nd quarter. Toronto Dominion Bank now owns 195,180 shares of the medical instruments supplier’s stock valued at $11,818,000 after purchasing an additional 32,485 shares during the last quarter. Finally, Atlantic Trust LLC lifted its holdings in Baxter International by 2.1% during the 2nd quarter. Atlantic Trust LLC now owns 42,430 shares of the medical instruments supplier’s stock valued at $2,609,000 after purchasing an additional 891 shares during the last quarter. 83.12% of the stock is owned by institutional investors.
In related news, SVP Giuseppe Accogli sold 28,641 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total value of $1,918,947.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Jeanne K. Mason sold 33,350 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $65.25, for a total value of $2,176,087.50. Following the completion of the transaction, the senior vice president now owns 124,609 shares in the company, valued at approximately $8,130,737.25. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by company insiders.
Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $0.64 EPS for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.12% and a net margin of 6.79%. The company had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.77 billion. During the same quarter last year, the business earned $0.57 earnings per share. Baxter International’s revenue was up 4.9% on a year-over-year basis. research analysts forecast that Baxter International Inc will post 2.78 EPS for the current fiscal year.
Several brokerages have issued reports on BAX. Citigroup raised their price target on Baxter International from $66.00 to $70.00 and gave the company a “neutral” rating in a report on Tuesday, February 6th. Royal Bank of Canada reaffirmed a “hold” rating and set a $72.00 price target on shares of Baxter International in a report on Friday, February 2nd. Barclays raised their price target on Baxter International from $73.00 to $77.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. BMO Capital Markets raised their price target on Baxter International from $74.00 to $77.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Finally, Zacks Investment Research raised Baxter International from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $70.36.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.